

ARRAY BIOPHARMA INC  
Form 8-K  
January 22, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 22, 2018 (January 20, 2018)**

**Array BioPharma Inc.**

*(Exact name of registrant as specified in its charter)*

**Delaware**

*(State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)*

**001-16633**

**84-1460811**

**3200 Walnut Street, Boulder, Colorado 80301**

*(Address of principal executive offices, including Zip Code)*

**(303) 381-6600**

*(Registrant's telephone number, including area code)*

*(Former name or former address, if changed since last report)*

Edgar Filing: ARRAY BIOPHARMA INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

In this report, “Array BioPharma,” “Array,” “we,” “us” and “our” refer to Array BioPharma Inc., unless the context otherwise provides.

**Item 8.01 Other Events.**

On January 20, 2018, Array issued a press release announcing data from the Phase 3 BEACON CRC Safety Lead-In trial in *BRAF*-Mutant Colorectal Cancer that was presented at the ASCO 2018 Gastrointestinal Cancers Symposium.

A copy of the press release is attached to this Form 8-K as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

**Exhibit No. Description**

|             |   |
|-------------|---|
| <u>99.1</u> | <u>Press release announcing results from the Phase 3 BEACON CRC Safety Lead-In trial in <i>BRAF</i>-Mutant Colorectal Cancer presented at the ASCO 2018 Gastrointestinal Cancers Symposium.</u> |
|-------------|---|

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 22, 2018 Array BioPharma Inc.

By: /s/ Jason Haddock  
Jason Haddock  
Chief Financial Officer

**EXHIBIT INDEX**

**Exhibit No. Description**

99.1 Press release announcing results from the Phase 3 BEACON CRC Safety Lead-In trial in *BRAF*-Mutant Colorectal Cancer presented at the ASCO 2018 Gastrointestinal Cancers Symposium.